Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Atacicept in Multiple Autoimmune Glomerular Diseases (PIONEER)
NCT06983028Phase 2Recruiting
- Sponsor
- Vera Therapeutics
- Start
- Jul 2025
- Primary completion
- Nov 2027
- Modality
- Fc-Fusion Proteins
- Countries
- 1
01
Overview
A Phase 2 trial of atacicept in IgA nephropathy (IgAN), primary membranous nephropathy (PMN), minimal change disease (MCD), focal segmental glomerulosclerosis (FSGS), nephrotic syndrome, sponsored by Vera Therapeutics. Started Jul 2025; status: recruiting.
02
Drugs
atacicept
03
Conditions
IgA nephropathy (IgAN)primary membranous nephropathy (PMN)minimal change disease (MCD)focal segmental glomerulosclerosis (FSGS)nephrotic syndrome
Beyond the preview
Go deeper on NCT06983028.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06983028.